Dealbreaker on MSN19d
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood ClotsThe Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs.
We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it selected for negotiation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback